Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Lemierre's Syndrome Bacteria Are Responsible for Many Cases of Sore Throat Among Adolescents in the US

By LabMedica International staff writers
Posted on 23 Feb 2015
A recent study conducted at a student health clinic in the United States found that more cases of severe sore throat (pharyngitis) among young adults were caused by the bacterium Fusobacterium necrophorum than by hemolytic streptococci or by Mycoplasma pneumoniae.

The anaerobic bacterium F. necrophorum was shown in European studies to account for about 10% of sore throats and was the primary cause of Lemierre's syndrome.

Lemierre's syndrome develops most often after a sore throat caused by some bacterium of the Streptococcus genus has created a peritonsillar abscess, a pocket filled with pus and bacteria near the tonsils. Deep in the abscess, anaerobic bacteria like F. necrophorum can flourish. The bacteria penetrate from the abscess into the neighboring jugular vein in the neck and there they cause an infected clot to form, from which bacteria are seeded throughout the body by the bloodstream. Bits of the infected clot break off and travel to the lungs as emboli where they block branches of the pulmonary artery bringing deoxygenated blood from the heart to the lungs. This causes shortness of breath, chest pain, and severe pneumonia. The syndrome affects mostly adolescents and young adults and is seen rarely in pre-adolescents. It often causes long, complex hospitalizations requiring intensive care, and although the organism is usually sensitive to penicillin and other antibiotics, about 6% of those contracting Lemierre’s syndrome die.

As there is little available data regarding F. necrophorum infection in the US, investigators at the University of Alabama (Birmingham, USA) used an in-house PCR assay to identify four different pathogenic microorganisms in throat swabs from 312 students aged 15 to 30 years presenting to a student health clinic with an acute sore throat and 180 asymptomatic students.

Results revealed that F. necrophorum was detected in 20.5% of patients and 9.4% of asymptomatic students. Group A beta-hemolytic Streptococcus was detected in 10.3% of patients and 1.1% of asymptomatic students. Group C/G beta-hemolytic Streptococcus was detected in 9.0% of patients and 3.9% of asymptomatic students. Mycoplasma pneumoniae was detected in 1.9% of patients and none of the asymptomatic students.

“This is the first study in the United States that shows that F. necrophorum causes a significant number of cases of pharyngitis in this young adult population,” said first author Dr. Robert M. Centor, professor of general internal medicine at the University of Alabama. “It is also the first to show that F. necrophorum pharyngitis and Streptococcus pharyngitis share similar clinical signs. This study bolsters our understanding that this condition is common in the US and very closely resembles strep throat.”

“It is not just about strep throat in this 15–30 age group,” said Dr. Centor. “Physicians have to consider F. necrophorum, which in our study caused more sore throats than strep. And, F. necrophorum is itself associated with a potentially devastating complication, which while rare, is a more common side effect that acute rheumatic fever. This is the first step in a series of studies that need to be done to define the prevalence and extent of F. necrophorum and how it presents clinically. A very important next step is to develop a practical and affordable point-of-care test for F. necrophorum.

The study was published in the February 17, 2015, online edition of the journal Annals of Internal Medicine.

Related Links:
University of Alabama



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.